Niosome encapsulated of vincristine sulfate: improved anticancer activity with reduced toxicity in mice.
Nonionic surfactant vesicles (niosomes) are promising drug carriers for anticancer drugs. Niosome encapsulated vincristine sulfate prepared by transmembrane pH gradient drug uptake process (remote loading method) was evaluated for toxicity and antitumour activity after administration to tumour bearing mice. The toxicity of vincristine sulfate was reduced after niosome encapsulation and anticancer activity improved, which may be due to better delivery of vincristine at the tumour site.
Parthasarathi
G
G
College of Pharmaceutical Sciences, K.M.C., Manipal, India.
Udupa
N
N
Umadevi
P
P
Pillai
G K
GK
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001772:Blood Cell Count; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy / Q000473:pathology; D003402:Creatine Kinase / Q000097:blood; D004337:Drug Carriers; D004339:Drug Compounding; D005684:Gait / Q000187:drug effects; D006863:Hydrogen-Ion Concentration; D007770:L-Lactate Dehydrogenase / Q000097:blood; D051379:Mice; D008807:Mice, Inbred BALB C; D015162:Micronucleus Tests; D009422:Nervous System Diseases / Q000139:chemically induced / Q000473:pathology; D009431:Neural Conduction / Q000187:drug effects; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000473:pathology; D004856:Postural Balance / Q000187:drug effects; D012510:Sarcoma 180 / Q000188:drug therapy / Q000473:pathology; D013501:Surface-Active Agents / Q000737:chemistry; D014750:Vincristine / Q000008:administration & dosage* / Q000627:therapeutic use* / Q000633:toxicity
D004337:Drug Carriers; D013501:Surface-Active Agents; D014750:Vincristine; D007770:L-Lactate Dehydrogenase; D003402:Creatine Kinase